BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

CS Genetics and ROSALIND® Join Forces to Expand Access to Single-Cell Genomics

NextEdge Admin

20 Sep 2024

2 min 10 sec

CS Genetics, a genomics technology company, has announced a strategic partnership with ROSALIND®, a leading SaaS platform in life science research. This collaboration merges the simplicity of CS Genetics' SimpleCell™ platform with ROSALIND®'s advanced multi-omics analysis, providing researchers with expanded single-cell capabilities at a significantly reduced cost.

Jay Harger, Chief Operating Officer of CS Genetics, emphasized that the SimpleCell™ platform redefines single-cell genomics by eliminating the need for costly instruments and drastically lowering per-sample expenses. "Our partnership with ROSALIND® allows biopharma and academic teams to undertake larger, more rigorous single-cell projects while benefiting from top-tier analysis and collaboration tools," he stated.

The SimpleCell™ platform employs a novel, instrument-free approach powered by Kinetic Confinement, integrating seamlessly into standard lab workflows. This enables biopharma and academic researchers to conduct larger-scale studies with greater speed and cost efficiency.

Tim Wesselman, CEO of ROSALIND®, highlighted that CS Genetics addresses key barriers to single-cell genomics: complexity and cost. He noted that this collaboration not only accelerates research but also maximizes return on investment by empowering more projects and fostering larger scientific teams.

Together, CS Genetics and ROSALIND® aim to democratize single-cell genomics, making this technology accessible to more researchers while enhancing scientific discovery and collaboration.

CS Genetics is based in Cambridge, UK, and San Diego, CA, and specializes in innovative, scalable genomics solutions.